MAK683
oral, allosteric PRC2 inhibitor (EED) in Ph. I/II for cancer (DLBCL); preliminary efficacy from micromolar HTS hit J. Med. Chem., March 30, 2022 Novartis, Emeryville, CA
Molecules of the Month - March 2022
Molecules of the Month
- rilzabrutinib (PRN1008)
- INE963
- ulevostinag (MK-1454)
- compound 24
- compound 10
- etavopivat
- BMS-986176/LX-9211
- branaplam
- MAK683
- HR1405-01